Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05837663 · ClinicalTrials.gov registry record
Trifecta-Lung cfDNA-MMDx Study
A clinical trial of Lung Transplantation, sponsored by University of Alberta.
- Recruiting
- Registry status
- 600
- Enrollment target
- 18
- Study locations
NCT05837663: Recruiting study of Lung Transplantation, sponsored by University of Alberta.
NCT05837663 is a study of Lung Transplantation that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 600 participants, above the 286-participant average among 12 other Lung Transplantation trials with a reported enrollment target (110% higher). The trial reports 18 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05837663, a study of Lung Transplantation, is actively recruiting participants, sponsored by University of Alberta.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 18
- Study locations
Study Summary
Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.
Primary Outcome
Set dd-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy (TBB and 3BMB) as reported by MMDx. Calibration of dd-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx.
Conditions Studied
Study Locations (18)
Texas
- BAYLOR SCOTT & WHITE RESEARCH INSTITUTE , 3409 Worth Street - Dallas
- UT Southwestern Medical Center, 5939 Harry Hines Blvd. - Dallas
- Houston Methodist Lung Transplant Center, 6550 Fannin St., SM1001 - Houston
- UT Health San Antonio 7703 Floyd Curl Drive, MSC: 7858 - San Antonio
Other
- The Alfred Hospital, Monash University - Melbourne
- Department of Thoracic Surgery, Medical University of Vienna - Vienna
- Motol University Hospital, V Uvalu 84 - Prague
- Charles University/Hospital Motol - Prague
Florida
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, College of Medicine - Gainesville
- USF Health, Morsani College of Medicine, 12901 Bruce B. Downs Blvd. MDC40 - Tampa
Alberta
- Department of Medicine, University of Alberta - Edmonton
- Alberta Transplant Applied Genomics Centre, University of Alberta - Edmonton
Arizona
- St. Joseph's Hospital and Medical Center 350 West Thomas Road, Floor 8HLT - Phoenix
Indiana
- Indiana University Methodist Hospital 1812 N. Capitol Ave Suite W131L - Indianapolis
Maryland
- Johns Hopkins Interventional Pulmonology, Sheikh Zayed Tower, Room 7125L, 1800 Orleans Street - Baltimore
New York
- Division of Pulmonary, Allergy & Critical Care Medicine Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2027-12 |
What NCT05837663 shows while recruiting
NCT05837663 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 286-participant average among 12 other Lung Transplantation trials with a reported enrollment target (110% higher).
The record links to 1 condition, with Lung Transplantation appearing as the primary indexed condition, and to 0 interventions.
NCT05837663 lists 18 locations in 10 states (Texas, Other, Florida).
Frequently Asked Questions
What is clinical trial NCT05837663 about?
NCT05837663 is a clinical study titled "Trifecta-Lung cfDNA-MMDx Study". Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.
What is the current status of trial NCT05837663?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2023-11-01. Estimated completion is 2027-12.
What conditions does trial NCT05837663 study?
This clinical trial studies the following conditions: Lung Transplantation.
Who is sponsoring clinical trial NCT05837663?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05837663 being conducted?
This trial has 18 study locations across Arizona, Florida, Indiana, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05837663's enrollment target sits among peer trials
600 3rd of 12 higher than 10 of 12 other Lung Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
RECRUITING
-
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
RECRUITING · Phase 2
-
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
RECRUITING
-
Transplanting Lungs From Uncontrolled Donation After Circulatory Death
RECRUITING · NA
-
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
RECRUITING · Phase 2
-
OCS™ Lung TOP Registry For Donor Lungs for Transplantation
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI